{"nctId":"NCT01626456","briefTitle":"A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)","startDateStruct":{"date":"2012-06"},"conditions":["Schizophrenia"],"count":478,"armGroups":[{"label":"ALKS 9072, Low","type":"EXPERIMENTAL","interventionNames":["Drug: ALKS 9072, Low"]},{"label":"ALKS 9072, High","type":"EXPERIMENTAL","interventionNames":["Drug: ALKS 9072, High"]}],"interventions":[{"name":"ALKS 9072, Low","otherNames":[]},{"name":"ALKS 9072, High","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n(Subjects who participated in ALK9072-003)\n\n* Completed the ALK9072-003 Day 85 visit\n* Continues to require treatment with an antipsychotic medication\n\n(New Subjects)\n\n* On a stable dose of oral antipsychotic medication\n* Diagnosis of chronic schizophrenia based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria that is clinically stable\n* Has been able to achieve outpatient status for more than 3 months prior to screening\n* Body Mass Index (BMI) of 18.5 to 40.0 kg/m2 (inclusive)\n* Resides in a stable living situation\n\nExclusion Criteria:\n\n(Subjects who participated in ALK9072-003)\n\n* Abnormal clinical laboratory, vital sign, or electrocardiogram (ECG) finding during participation in study ALK9072-003 that was clinically relevant and related to study drug\n* Missed more than 1 scheduled study visit during participation in study ALK9072-003\n* Has a significant or unstable medical condition that would preclude safe completion of the current study\n* Subject is pregnant or breastfeeding\n* Subject expects to be incarcerated in the next 12 months, or has pending legal action which may impact compliance with study participation or procedures\n\n(New Subjects)\n\n* History of poor or inadequate clinical response to treatment with aripiprazole\n* History of treatment resistance\n* Diagnosis of current substance dependence (including alcohol)\n* Pregnant, lactating, or breastfeeding\n* Has received any long-acting intramuscular antipsychotic medication within 60 days prior to screening\n* Currently under involuntary hospitalization\n* Current or expected incarceration\n\nAdditional inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Treatment-emergent Adverse Events (TEAEs)","description":"This measure includes incidences \\>5%.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"190","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Endpoint in Clinical Global Impression Scale for Severity (CGI-S)","description":"The CGI-S is a 7-point scale that requires the clinician to assess how mentally ill the patient is in a specific point in time. Results indicate participants evaluated at one of the following categories: \"1: normal, not at all ill\"; \"2: borderline mentally ill\"; \"3: mildly ill\"; \"4: moderately ill\"; \"5: markedly ill\"; \"6: severely ill\"; and \"7: among the most extremely ill patients\". Results indicate a change in CGI-S score from baseline to Day 365 based on the observed data.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"0.68"},{"groupId":"OG001","value":"-0.5","spread":"0.71"},{"groupId":"OG002","value":"-0.8","spread":"0.85"},{"groupId":"OG003","value":"-0.3","spread":"0.61"},{"groupId":"OG004","value":"-0.2","spread":"0.61"}]}]}]},{"type":"SECONDARY","title":"Discontinuation From Study Due to Adverse Events (AEs)","description":"Number of subjects who discontinued the study due to AE.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Suicidal Ideation and Behavior Using the Columbia Suicide Severity Rating Scale (C-SSRS)","description":"The C-SSRS is a questionnaire used for suicide assessment. Subjects are asked a series of questions that determine whether or not the patient demonstrates any suicidal ideation or behavior. The C-SSRS was administered to subjects at each study visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Clinically Significant Changes Will be Calculated for Movement Disorders, Vital Signs and Routine Laboratory Tests","description":"Includes incidence \\>2% but \\<5%.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Endpoint Using the Positive and Negative Symptom Scale (PANSS) Total Score and Subscale Scores","description":"This scale consists of symptom constructs (7 positive, 7 negative, 16 general psychopathology), each to be rated on a 7-point Likert-type scale of severity with 1 being absent to 7 being extreme. Minimum scores (best outcome) equals 30 (total scale), 7 (positive/negative subscales), and 16 (general subscale); maximum scores (worst outcome) equals 210 (total scale), 49 (positive/negative subscales), and 112 (general subscale).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.1","spread":"15.5"},{"groupId":"OG001","value":"-10.0","spread":"10.2"},{"groupId":"OG002","value":"-11.6","spread":"11.7"},{"groupId":"OG003","value":"-8.3","spread":"8.2"},{"groupId":"OG004","value":"-5.9","spread":"8.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.8","spread":"6.0"},{"groupId":"OG001","value":"-3.4","spread":"3.4"},{"groupId":"OG002","value":"-4.1","spread":"4.1"},{"groupId":"OG003","value":"-2.3","spread":"3.1"},{"groupId":"OG004","value":"-1.8","spread":"2.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.1","spread":"4.2"},{"groupId":"OG001","value":"-1.5","spread":"3.5"},{"groupId":"OG002","value":"-1.6","spread":"3.8"},{"groupId":"OG003","value":"-2.1","spread":"3.0"},{"groupId":"OG004","value":"-1.2","spread":"3.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.2","spread":"7.6"},{"groupId":"OG001","value":"-5.1","spread":"5.6"},{"groupId":"OG002","value":"-5.9","spread":"6.1"},{"groupId":"OG003","value":"-4.0","spread":"4.7"},{"groupId":"OG004","value":"-2.9","spread":"4.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":110},"commonTop":["Insomnia","Weight increased","Headache"]}}}